Synopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets
|
|
- Jewel Shaw
- 5 years ago
- Views:
Transcription
1 Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study centers Related publications Study period (Date of obtaining first subject s informed consent - Date of completing the study treatment in the last subject) Phase of development Objective of the study Method of the study Number of subjects (planned and analyzed) Main entrance criteria HD Candesartan cilexetil/ amlodipine besylate Double-blind study of TCV-116 and amlodipine besylate in patients with mild/moderate essential hypertension 20 study centers Manuscript in preparation Date of first consent among subjects included in the treatment period: December 16, 2006 Date of last observation of last subject: December 25, 2007 Phase III To evaluate the efficacy and safety of the concomitant use of TCV-116 and amlodipine besylate in patients with mild/moderate essential hypertension by double-blind comparison. Multicenter, double-blind, randomized, parallel-group comparative study (Planned) Number of randomized subjects: 425 patients Number of subjects included in primary endpoint evaluation: 375 patients (Analyzed) Number of randomized subjects: 444 patients Full Analysis Set (FAS): 444 patients Safety Analysis Set: 444 patients Inclusion criteria: (1) Patients with mild/moderate essential hypertension. (2) Blood pressure: A sitting diastolic blood pressure of 90 mmhg and < 110 mghg and a sitting systolic blood (3) Age: 20 years. (4) Gender: male or female. (5) Patient status: outpatient. pressure of 140 mmhg and < 180 mmhg at two points during the control observation period.
2 (6) Able to understand this study and to comply with the procedure of it. (7) Able to give written consent to participate in this study prior to participation. Exclusion criteria: Subjects who met any of the following criteria were excluded from the study. (1) Patients with secondary hypertension, severe hypertension or malignant hypertension. (2) Patients received concomitant therapy with more than 3 different types of antihypertensives within 4 weeks prior to the control observation period. (3) Patients received concomitant therapy with candesartan cilexetil and amlodipine besylate within 4 weeks prior to the control observation period. (4) Pregnant women, lactating women, woman of child-bearing potential, or women planning to become pregnant. (5) Patients with a history of hypersensitivity to an ARB or Ca antagonist. (6) Patients with a clinically defined hepatic disorder. (7) Patients with a clinically defined renal disorder. (8) The following serious diseases or symptoms among the cardiovascular complications listed as factors influencing prognosis in the WHO-ISH Guidelines for the Management of Hypertension, Heart diseases: Myocardial infarction, coronary arterial revascularization, angina pectoris, congestive heart failure, arrhythmia requiring treatment, valve stenosis and atrial fibrillation 2. Cerebrovascular disorders: Cerebral infarction/cerebral hemorrhage and transient cerebral ischemia attack 3. Renal diseases: Renal failure and severe renal disorders 4. Vascular diseases: Dissecting aortic aneurysm and arteriosclerosis obliterans 5. Advanced hypertensive retinopathy: Hemorrhages, exudates
3 or papilledema (9) Patients with hyperkalemia. (10) Patients with a malignant tumor. (11) Patients with drug abuse or dependence or with a history of drug abuse or dependence. (12) Patients received another investigational product within 12 weeks prior to the control observation period. (13) Other patients judged inappropriate for entry in this study by the investigator or subinvestigator. Test product, dose and mode of administration, and batch number Investigational products - TCV-116 tablets (each tablet contains 4 or 8 mg of candesartan cilexetil) - TCV-116 placebo tablets (indistinguishable from TCV-116 tablets in appearance) - Amlodipine besylate capsules (each capsule contains any of the following combinations of amlodipine besylate 2.5 mg and placebo [2 tablets in total], and were indistinguishable in appearance from each other). - 0-mg capsules: Each capsule contains two placebo tablets of amlodipine besylate mg capsules: Each capsule contains one amlodipine besylate 2.5 mg tablet and one placebo tablet of amlodipine besylate [2 tablets in total]. - 5-mg capsules: Each capsule contains two amlodipine besylate 2.5 mg tablets. Dose and mode of administration: During the control observation period, one TCV-116 placebo tablet and one amlodipine besylate capsule were simultaneously administered once daily. During the treatment period, a combination of one TCV , 4- or 8-mg tablet and one amlodipine besylate 0-, 2.5- or 5-mg capsule were administered simultaneously once daily (0 mg/0 mg, 8 mg/0 mg, 4 mg/2.5 mg, 8 mg/2.5 mg, 0 mg/5 mg, 4 mg/5 mg, 8 mg/5 mg). Batch numbers: Investigational products for the control observation period (TCV-116 placebo tablets and amlodipine besylate capsules): Z
4 Duration of Treatment Endpoint Investigational products for the treatment period (TCV-116 tablets, TCV-116 placebo tablets and amlodipine besylate capsules): DB Four weeks of control observation and 12 weeks of treatment Efficacy Primary endpoint Trough sitting diastolic blood pressure Secondary endpoint Trough sitting systolic blood pressure Statistical Methods Safety Adverse events, vital signs, body weight, resting 12-lead ECG and laboratory tests Analyses of efficacy endpoints (1) Primary analysis of the primary endpoint The following analyses were performed using the Full Analysis Set (FAS). i) Summary statistics for the trough sitting diastolic blood pressure (change from the end of the control observation period at the end of the treatment period) and 95% confidence interval for the mean were calculated for each group. The mean and standard deviations were displayed as a graph. ii) The data were analysed using the following response surface method. Change in trough sitting diastolic blood pressure (the end of the treatment period the end of the control observation period) = β 0 + β 1 D TCV β 2 D amlodipine besylate + ε where, DTCV-116 and D amlodipine besylate are the daily dose of TCV-116 and amlodipine besylate, respectively. β 1 and β 2 are the parameters indicating the first-order dose-response relationship of TCV-116 and amlodipine besylate, respectively. ε is an error variable. Using the above model, the estimate, standard error and p-value of each parameter were calculated. For reference, designating the above model as the initial model, the final model was selected by the hierarchical step-up method using a significance level of 10% (two-sided) for the second-order term or
5 interaction term of TCV-116 and amlodipine besylate. The following analyses were performed using the final model. 1. The estimate, standard error and p-value of each parameter were calculated. 2. Using this model, the mean change in trough sitting diastolic blood pressure at each dose (0 mg/0 mg, 8 mg/0 mg, 4 mg/2.5 mg, 8 mg/2.5 mg, 0 mg/5 mg, 4 mg/5 mg, 8 mg/5 mg) and its two-sided 95% confidence interval were estimated. 3. A response surface was estimated within the dose ranges of TCV-116 (0 to 8 mg) and amlodipine besylate (0 to 5 mg) and displayed as a graph. (2) Secondary analyses of the primary endpoint i) The point estimate of the mean in each group in the FAS and its two-sided 95% confidence interval were calculated using a one-way analysis of variance, with treatment group (0 mg/0 mg, 8 mg/0 mg, 4 mg/2.5 mg, 8 mg/2.5 mg, 0 mg/5 mg, 4 mg/5 mg, 8 mg/5 mg) as the independent variable. In addition, the point estimate of the inter-group difference (concomitant therapy [8 mg/5 mg] group each monotherapy [8 mg/0 mg and 0 mg/5 mg] group) in the mean trough sitting diastolic blood pressure and its two-sided 95% confidence interval were calculated. A contrast test (comparison between 8 mg/0 mg and 8 mg/5 mg) using a contrast coefficient (0, -1, 0, 0, 0, 0, 1) and a contrast test (comparison between 0 mg/5 mg and 8 mg/5 mg) using a contrast coefficient (0, 0, 0, 0, -1, 0, 1) were performed for the groups (0 mg/0 mg, 8 mg/0 mg, 4 mg/2.5 mg, 8 mg/2.5 mg, 0 mg/5 mg, 4 mg/5 mg, 8 mg/5 mg). (3) Secondary endpoint The data regarding the secondary endpoint were subjected to the same analyses as the primary analysis and the secondary analyses of the primary endpoint. Analyses of the safety endpoints Adverse events in the Safety Analysis Set were summarized. The
6 incidence of adverse events was summarized by causality with the investigational product for the treatment period for each group. For the safety evaluation, the incidence of adverse events was analyzed by the χ-square test for a contingency table between groups. The incidence of adverse events was determined in two situations, i.e., when events not related to the investigational product for the treatment period were included or excluded. For each symptom/sign handled as an adverse event, the incidence was summarized by causality with the investigational product for the treatment period, by severity and causality with the investigational product for the treatment period, and by onset time and causality with the investigational product for the treatment period for each group. Summary results and conclusion Efficacy 1. Primary endpoint The change (mean ± standard deviation) from the end of the control observation period in trough sitting diastolic blood pressure at the end of the treatment period was ± mmhg in the 4 mg/2.5 mg group, ± mmhg in the 4 mg/5 mg group, ± mmhg in the 8 mg/2.5 mg group, ± mmhg in the 8 mg/5 mg group, ± mmhg in the 8 mg/0 mg group, ± mmhg in the 0 mg/5 mg group and ± mmhg in the 0 mg/0 mg group. The results of the analysis using the initial response surface model are shown below. The estimates of the first-order effects of the daily doses of TCV-116 and amlodipine besylate were (S.E. = 0.108, p<0.0001) and (S.E. = 0.172, p<0.0001), respectively. In the final model, the first-order effects of the daily doses of TCV-116 and amlodipine besylate, and the second-order effect of the daily dose of TCV-116 were included. The interaction term of the daily doses of TCV-116 and amlodipine besylate was not included in this model. The estimates of the first-order effects of the daily doses of TCV-116 and amlodipine besylate were (S.E. = 0.529, p=0.0021) and (S.E. = 0.172, p<0.0001), respectively. The estimate of the second-order effect of the daily dose of TCV-116 was (S.E. = 0.064, p<0.0464). The estimates of the mean change in trough sitting diastolic blood pressure at each dose and its 95% confidence interval
7 determined using the final model were (95% CI, to ) mmhg in the 4 mg/2.5 mg group, (95% CI, to ) mmhg in the 4 mg/5 mg group, (95% CI, to ) mmhg in the 8 mg/2.5 mg group, (95% CI, to ) mmhg in the 8 mg/5 mg group, (95% CI, to ) mmhg in the 8 mg/0 mg group, (95% CI, to ) mmhg in the 0 mg/5 mg group and (95% CI, to ) mmhg in the 0 mg/0 mg group. The change from the end of the control observation period in trough sitting diastolic blood pressure at the end of the treatment period was analyzed by the one-way ANOVA model. The point estimates of the inter-group difference (concomitant therapy [8 mg/5 mg] group each monotherapy [8 mg/0 mg and 0 mg/5 mg] group) in the mean trough sitting diastolic blood pressure and its two-sided 95% confidence interval were (95% CI, to ) for the difference between the 8 mg/5 mg and 8 mg/0 mg groups, and (95% CI, to ) for the difference between the 8 mg/5 mg and 0 mg/5 mg groups. The contrast test revealed a significant difference between the 8 mg/5 mg and 8 mg/0 mg groups (p<0.0001), and between the 8 mg/5 mg and 0 mg/5 mg groups (p<0.0001). 2. Secondary endpoint The change from the end of the control observation period in trough sitting systolic blood pressure at the end of the treatment period was ± mmhg in the 4 mg/2.5 mg group, ± mmhg in the 4 mg/5 mg group, ± mmhg in the 8 mg/2.5 mg group, ± mmhg in the 8 mg/5 mg group, ± mmhg in the 8 mg/0 mg group, ± mmhg in the 0 mg/5 mg group and ± mmhg in the 0 mg/0 mg group. In contrast, the results of the analysis using the initial response surface model are shown below. The estimates of the first-order effects of the daily doses of TCV-116 and amlodipine besylate were (S.E. = 0.152, p<0.0001) and (S.E. = 0.243, p<0.0001), respectively. The final model was the same as the initial model in that the interaction term of the daily doses of TCV-116 and amlodipine besylate was not
8 included. In addition, the model selected for analyses was the same as the initial model. The estimates of the mean change in trough sitting systolic blood pressure at each dose and its 95% confidence interval determined using the final model were (95% CI, to ) mmhg in the 4 mg/2.5 mg group, (95%CI, to ) mmhg in the 4 mg/5 mg group, (95%CI, to ) mmhg in the 8 mg/2.5 mg group, (95%CI, to ) mmhg in the 8 mg/5 mg group, (95%CI, to ) mmhg in the 8 mg/0 mg group, (95%CI, to ) mmhg in the 0 mg/5 mg group and (95%CI, to ) mmhg in the 0 mg/0 mg group. The change from the end of the control observation period in trough sitting systolic blood pressure at the end of the treatment period was analyzed by the one-way ANOVA model. The estimate of the inter-group difference (concomitant therapy [8 mg/5 mg] group each monotherapy [8 mg/0 mg and 0 mg/5 mg] group) in the mean trough sitting systolic blood pressure and its two-sided 95% confidence interval was (95% CI, to ) for the difference between the 8 mg/5 mg and 8 mg/0 mg groups, and (95%CI, to ) for the difference between the 8 mg/5 mg and 0 mg/5 mg groups. The contrast test revealed a significant difference between the 8 mg/5 mg and 8 mg/0 mg groups (p<0.0001), and between the 8 mg/5 mg and 0 mg/5 mg groups (p<0.0001). Safety One subject in the 8 mg/0 mg group died during the treatment period. One other serious adverse event occurred in the 8 mg/0 mg group during the treatment period. These events were not related to the investigational product in the investigator s opinion. Two events in two subjects in the 8 mg/0 mg group, including the above death, led to the withdrawal of treatment during the treatment period. Neither event was deemed to be related to the investigational product. The incidence of adverse events including those not related to the investigational product was 44.6% (45/101) in the 8 mg/5 mg group, 47.2% (17/36) in the 8 mg/2.5 mg group, 42.0% (42/100) in the 8 mg/0 mg group, 49.0% (49/100) in the 0 mg/5 mg group, 44.4% (16/36) in
9 the 0 mg/0 mg group, 41.7% (15/36) in the 4 mg/5 mg group and 45.7% (16/35) in the 4 mg/2.5 mg group. The differences in the incidence of adverse events among the groups were not significant (p = ). The incidence of adverse events excluding those not related to the investigational product was 7.9% (8/101) in the 8 mg/5 mg group, 5.6% (2/36) in the 8 mg/2.5 mg group, 10.0% (10/100) in the 8 mg/0 mg group, 7.0% (7/100) in the 0 mg/5 mg group, 8.3% (3/36) in the 0 mg/0 mg group, 2.8% (1/36) in the 4 mg/5 mg group and 5.7% (2/35) in the 4 mg/2.5 mg group. The differences in the incidence of adverse events among the groups were not significant (p = ). The types and severity of the adverse events commonly observed in this study were similar to those already reported in the package inserts of TCV-116 and amlodipine besylate. With the exception of the death in the 8 mg/0 mg group during the treatment period, all adverse events were mild or moderate. No severe adverse events occurred. Conclusion Concomitant therapy with TCV-116 and amlodipine besylate (8 mg/5 mg) given orally once daily for 12 weeks is expected to have a sufficient therapeutic effect and a good safety profile in patients with mild/moderate essential hypertension. Date of Report June 3, 2011
Period of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationJMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.219 Comparative Study of Adverse Effect of
More informationIJBCP International Journal of Basic & Clinical Pharmacology. Adverse drug effects monitoring of amlodipine in a tertiary care hospital
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20182069 Original Research Article Adverse drug
More information17 th Club Phase 1 Annual Meeting April 5, Pierre Maison-Blanche Hopital Bichat, Paris, France
Practical Issues for the clinical evaluation of QT/QTc interval prolongation 17 th Club Phase 1 Annual Meeting April 5, 2018 Pierre Maison-Blanche Hopital Bichat, Paris, France Disclosure Chiesi Pharmaceuticals
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 January 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 January 2008 ZANIDIP 10mg, film-coated tablets B/28 (CIP: 347 638.7) B/30 (CIP: 372 259.6) B/90 (CIP: 372 260.4)
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 10 Mar 2019 06:52:14 GMT) CTRI Number Last Modified On 29/07/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationPRESCRIPTION PATTERN OF ANTI HYPERTENSIVE DRUGS IN SHRI SATHYA SAI MEDICAL COLLEGE & RESEARCH INSTITUTE
Original Article PRESCRIPTION PATTERN OF ANTI HYPERTENSIVE DRUGS IN SHRI SATHYA SAI MEDICAL COLLEGE & RESEARCH INSTITUTE Annamalai Maduram 1, Harikrishna 2 INTRODUCTION High blood pressure, termed "hypertension,"
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More information1 INDICATIONS AND USAGE. 1.1 Hypertension FULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMLODIPINE besylate tablets USP safely and effectively. See full prescribing information for AMLODIPINE
More informationDRUG INTERACTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMLODIPINE BESYLATE TABLETS safely and effectively. See full prescribing information for AMLODIPINE
More informationPage 1 of 21. Tablets: 2.5 mg, 5 mg, and 10 mg (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMLODIPINE BESYLATE TABLETS safely and effectively. See full prescribing information for AMLODIPINE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amodip 1.25 mg chewable tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Active substance:
More informationTolerance and safety of enalapril
Br. J. clin. Pharmac. (1984), 18, 249S-253S Tolerance and safety of enalapril W. McFATE SMITH, R. 0. DAVIES, M. A. GABRIEL, D. M. KRAMSCH, F. MONCLOA, JANET E. RUSH & J. F. WALKER Merck Sharp & Dohme Research
More informationDr. Omar S. Tabbouche, M.Sc, D.Sc, Pharm.D Head of Pharmacy Department New Mazloum Hospital Tripoli, Lebanon
Efficacy & Safety of Ketoprofen 25mg vs. Paracetamol 1g intravenous preparations in the management of fever in adults: A pilot, double-blind, parallel-group, randomized controlled trial Dr. Omar S. Tabbouche,
More informationPATIENT INFORMATION LEAFLET ACCEL-AMLODIPINE. Amlodipine Tablets 5 mg and 10 mg amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent
PATIENT INFORMATION LEAFLET Pr ACCEL-AMLODIPINE Amlodipine Tablets 5 mg and 10 mg amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent ACTION AND CLINICAL PHARMACOLOGY ACCEL-AMLODIPINE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pimovita 10 mg chewable tablets for dogs Pimovita vet.10 mg chewable tablets for
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationLABELLING AND PACKAGE LEAFLET
LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MILTEFORAN 20 mg/ml oral solution for dogs miltefosine 2.
More informationNL/H/880/01-02 FINAL SMPC
SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine ratiopharm tablets 5 mg, tablets Amlodipine ratiopharm tablets 10 mg, tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Amlodipine Bluefish 5 mg tablets Amlodipine Bluefish 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains
More informationAMLOPRESS SAJA PHARMA
08-15 AMLOPRESS SAJA PHARMA Amlodipine (as besylate) 5 mg Capsule for Oral Use 1. NAME OF THE MEDICINAL PRODUCT AMLOPRESS 5 mg Capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Capsule contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Istolde 10 mg tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 10 mg tablets: Each tablet contains 10 mg amlodipine (as besilate) For
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine 5 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg Amlodipine as Amlodipine Besilate. For full
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine 10 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg Amlodipine as Amlodipine Besilate. For
More informationSUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE
More informationShort Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil
Short Course Antibiotic Therapy of Streptococcal Pharyngitis: Comparison of Clarithromycin with Amoxicillin/ Clavulanate and Cefuroxime Axetil D. Adam, MD PhD, Munich, Germany H. Scholz, MD PhD, Berlin,
More informationSrirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.
Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid
More informationMaximum antihypertensive effects are attained within 2 weeks after a change in dose. AZOR may be administered with other antihypertensive agents.
Page 4 FULL PRESCRIBING INFORMATION AZOR (amlodipine and olmesartan medoxomil) tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin
More information1.3.1 Amlodipine besilate SPC, Labeling and Package Leaflet NL
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT 5 mg tablets 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 5 mg tablets: Each
More informationTHE VETERINARIAN'S CHOICE. Compendium clinical Trials. Introducing new MILPRO. from Virbac. Go pro. Go MILPRO..
THE VETERINARIAN'S CHOICE. Introducing new MILPRO from Virbac. Compendium clinical Trials Go pro. Go MILPRO.. milbemycin/praziquantel Content INTRODUCTION 05 I. EFFICACY STUDIES IN CATS 06 I.I. Efficacy
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationCHEMMART AMLODIPINE 2.5 mg, 5 mg, 10 mg TABLETS
CHEMMART AMLODIPINE 2.5 mg, 5 mg, 10 mg TABLETS Product Information Australia NAME OF THE MEDICINE Amlodipine besylate. DESCRIPTION Amlodipine besylate is a dihydropyridine derivative. Chemical Name: 3-ethyl
More informationNorvasc 5 & 10mg tablets
Norvasc 5 & 10mg tablets 1. Name of the medicinal product Norvasc 5& 10 mg Tablets 2. Qualitative and quantitative composition Each tablet contains amlodipine besilate equivalent to 5 and 10mg amlodipine.
More informationANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 1 AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR MOXIFLOXACIN CONTAINING
More informationNew Zealand Data Sheet. Apo-Amlodipine
New Zealand Data Sheet Apo-Amlodipine Presentation APO-AMLODIPINE 2.5mg are white to off-white, round unscored tablets, engraved APO on one side and AML over 2.5 on the other side. Each tablet typically
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT GALLIPRANT 20 mg tablets for dogs GALLIPRANT 60 mg tablets for dogs GALLIPRANT 100 mg tablets for dogs 2. QUALITATIVE
More informationOne Amlodipine KRKA 5 mg or 10 mg tablet contains amlodipine maleate equivalent to either 5 mg or 10 mg amlodipine per tablet.
1. NAME OF THE MEDICINAL PRODUCT Amlodipine KRKA 5 mg tablets Amlodipine KRKA 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One Amlodipine KRKA 5 mg or 10 mg tablet contains amlodipine maleate
More information1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
PACKAGE LEAFLET FOR: Dormilan solution for injection for dogs and cats [FR] Dormilan 1 mg/ml solution for injection for dogs and cats [DE, PT, UK] Reanest 1 mg/ml solution for injection for dogs and cats
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Amlotan 5 and 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Amlotan 5 mg tablets: Each tablet contains 5 mg amlodipine (as
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg tablets for dogs Cardalis 5 mg/40 mg tablets for dogs Cardalis 10 mg/80 mg tablets for dogs
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationNL/H/-882/ SUMMARY OF PRODUCT CHARACTERISTICS 1/13
SUMMARY OF PRODUCT CHARACTERISTICS 1/13 1 NAME OF THE MEDICINAL PRODUCT Amlodipine CT 5 mg, tabletten Amlodipine CT 10 mg, tabletten 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Amlodipine ratiopharm tablets
More informationAMLODIPINE BESYLATE + OLMESARTAN MEDOXOMIL. Dihydropyridine Ca channel blocker [Dhp-CCB] + Angiotensin II receptor blockage [ARB]
AMLODIPINE BESYLATE + OLMESARTAN MEDOXOMIL Dihydropyridine Ca channel blocker [Dhp-CCB] + Angiotensin II receptor blockage [ARB] ESH/ESC HT MANAGEMENT GUIDELINE 2013 DIAGNOSIS TARGET BP TARGET BP CONTROL
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationAssessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT,
Assessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT, Sylva LU SCHWAGER, Edward D STURROCK, Lubbe WIESNER, Brian
More informationFORMULATION AND EVALUATION OF S-(-)-AMLODIPINE BESYLATE AND NEBIVOLOL HYDROCHLORIDE TABLETS
Digest Journal of Nanomaterials and Biostructures Vol. 5, No 1, March 2010, p. 201 205 FORMULATION AND EVALUATION OF S-(-)-AMLODIPINE BESYLATE AND NEBIVOLOL HYDROCHLORIDE TABLETS S. A. SHAIKH *, S. S.
More informationAUSTRALIAN PRODUCT INFORMATION AMLO (AMLODIPINE BESILATE) UNCOATED TABLETS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
AUSTRALIAN PRODUCT INFORMATION AMLO (AMLODIPINE BESILATE) UNCOATED TABLETS 1 NAME OF THE MEDICINE Amlodipine besilate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION AMLO contains the active ingredient Amlodipine
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationDouble-Blind, Placebo-Controlled, Randomized Study of Dipyrone as a Treatment for Pyrexia in Horses
Double-Blind, Placebo-Controlled, Randomized Study of Dipyrone as a Treatment for Pyrexia in Horses Emily Sundman, DVM Ming Yin, PhD Tianhua Hu, PhD Melinda Poole, DVM Disclosures Sundman, Yin, Hu, and
More informationSUMMARY of PRODUCT CHARACTERISTICS
SUMMARY of PRODUCT CHARACTERISTICS 1. Name of the veterinary medicinal product HELM-EX Flavour Tablets 2. Qualitative and quantitative composition Each tablet contains: Active ubstances Praziquantel 50.0
More informationConsultation with stakeholders - Reassessment of reimbursement status for dihydropyridine calcium channel blockers - ATC group C08CA
Company Consultation with stakeholders - Reassessment of reimbursement status for dihydropyridine calcium channel blockers - ATC group C08CA The Danish Medicines Agency has assessed the question of the
More informationGuidelines for Treatment of Urinary Tract Infections
Guidelines for Treatment of Urinary Tract Infections Overview This document details the Michigan Hospital Medicine Safety (HMS) Consortium preferred antibiotic choices for treatment of uncomplicated and
More informationOriginal Article. Introduction. Korean Circulation Journal
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Valsartan 160 mg/amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPart II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)
Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationAMLODIPINE BESILATE / ATORVASTATIN CALCIUM
1. THERAPEUTIC CATEGORY Calcium Channel Blocker Lipid Regulating Agent AMLODIPINE BESILATE / ATORVASTATIN CALCIUM NORVASC PROTECT 2. FORMULATION Amlodipine besilate/atorvastatin calcium (Norvasc Protect)
More informationCLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
More informationUniversité catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium. Bayer Santé SAS, Loos, France
Communicating Comprehensive Safety Data Gained from Clinical Trials to the Scientific Community: Opportunities and Difficulties from an Example with Moxifloxacin P.M. Tulkens, 1 P. Arvis, 2 F. Kruesmann,
More informationPropofol vs Dexmedetomidine
Propofol vs Dexmedetomidine A highlight of similarities & differences Lama Nazer, PharmD, BCPS Critical Care Clinical Pharmacy Specialist King Hussein Cancer Center Outline Highlight similarities and differences
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardisure flavoured 10 mg Tablets For dogs (Austria, Belgium, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands,,
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Card box and package leaflet for brown glass bottle (Type 1) 1. NAME OF THE
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion SE/H/1397/01-05/DC Ramipril/Amlodipine Sandoz (ramipril/amlodipine) Applicant: Sandoz A/S This module reflects the scientific discussion for the approval
More informationAPO-AMLODIPINE/ATORVASTATIN 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40 & 10/80 TABLETS
APO-AMLODIPINE/ATORVASTATIN 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40 & 10/80 TABLETS NAME OF THE MEDICINE Amlodipine (as besylate) and Atorvastatin (as calcium propylene glycol solvate) Active Ingredient
More informationFrequently asked questions
Frequently asked questions At what stage of heart failure should Cardalis be used? Cardalis should be given as part of your standard heart failure therapy as soon as clinical signs (such as exercise intolerance,
More informationStudy of the Side effects profile of different antihypertensive drugs among the Hypertensive patient
Study of the Side effects profile of different antihypertensive drugs among the Hypertensive patient Shrestha RK 1, Khan GM 1, Thapa P 1, Koju R 2 1 Department of Pharmacy, Kathmandu University 2 Department
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NOSEDORM 5 mg/ml Solution for injection for dogs and cats [DE, ES, FR, PT] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationAmlodipin Bluefish 10 mg tablets. amlodipine
Package leaflet: Information for the user Amlodipin Bluefish 5 mg tablets Amlodipin Bluefish 10 mg tablets amlodipine Read all of this leaflet carefully before you start taking this medicine because it
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME NORVASC 5 mg and 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 mg coated tablet contains amlodipine besilate equivalent to 5 mg amlodipine. Each
More informationBacterial skin and soft tissues infections (SSTI) are one of the most common 1. infections among different age groups
Bacterial skin and soft tissues infections (SSTI) are one of the most common 1 infections among different age groups Gram-positive bacteria are the most frequently isolated pathogens from SSTI, with a
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. GENTAMICIN VISION 3 mg/g eye ointment Gentamicin
PACKAGE LEAFLET: INFORMATION FOR THE USER GENTAMICIN VISION 3 mg/g eye ointment Gentamicin Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to
More information[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cronyxin 50 mg/g Oral paste for horses (DE, AT, BE, EE, LV, LT, ES, FR, IE, IT, NL, PL, UK) Cronyxin vet
More information[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RABORAL V-RG 2. QUALITATIVE AND QUANTITATIVE COMPOSITION For 1 dose: Active substance: -
More informationSANDOZ AMLODIPINE PRODUCT MONOGRAPH. Amlodipine Besylate. Tablets 2.5 mg, 5 mg and 10 mg. Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr SANDOZ AMLODIPINE Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg Antihypertensive-Antianginal Agent Sandoz Canada Inc. Date of Revision: 145 Jules Léger December 1, 2017 Boucherville,
More informationPRODUCT MONOGRAPH. amlodipine besylate. Tablets 2.5, 5 and 10 mg. Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr GD -AMLODIPINE amlodipine besylate Tablets 2.5, 5 and 10 mg Antihypertensive-Antianginal Agent GenMed, a division of Pfizer Canada Inc. 17 300 Trans-Canada Highway Kirkland, Quebec
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationPRODUCT MONOGRAPH. amlodipine besylate. Tablets 2.5, 5 and 10 mg. Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr NORVASC amlodipine besylate Tablets 2.5, 5 and 10 mg Antihypertensive-Antianginal Agent PFIZER CANADA INC. 17 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Revision: September
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg chewable tablets for dogs Cardalis 5 mg/40 mg chewable tablets for dogs Cardalis 10 mg/80
More informationSAFETY PHARMACOLOGY: CARDIOVASCULAR TELEMETRY. Aileen Milne PhD, Manager, Safety Pharmacology
SAFETY PHARMACOLOGY: CARDIOVASCULAR TELEMETRY Aileen Milne PhD, Manager, Safety Pharmacology SAFETY PHARMACOLOGY SERVICES OVERVIEW Full Range of S7A and S7B studies herg assay Respiratory function plethysmography(rat/mouse)
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationPRODUCT MONOGRAPH SANDOZ AMLODIPINE. Amlodipine Besylate. Tablets 2.5 mg, 5 mg and 10 mg. Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr SANDOZ AMLODIPINE Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg Antihypertensive-Antianginal Agent Sandoz Canada Inc. Date of Revision: 145 Jules Léger September 25, 2015 Boucherville,
More informationPRODUCT MONOGRAPH. Pr AMLODIPINE. Amlodipine Besylate Tablets, House Standard. 5 mg and 10 mg. Amlodipine (as amlodipine besylate)
PRODUCT MONOGRAPH Pr AMLODIPINE Amlodipine Besylate Tablets, House Standard 5 mg and 10 mg Amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent JAMP Pharma Corporation Date of Preparation:
More informationApplicant Invented name Strength Pharmaceutical Form
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES. 1 Member State Marketing Authorisation
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) OPINION FOLLOWING AN ARTICLE 29 REFERRAL. Amlovita
European Medicines Agency COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) OPINION FOLLOWING AN ARTICLE 29 REFERRAL Amlovita International Non-Proprietary Name (INN): Amlodipine BACKGROUND INFORMATION*
More informationVeterinary Medicinal Product
Veterinary Medicinal Product Carprodyl Quadri 120 mg chewable tablets for dogs PART I B Pharmaceutical Form Chewable tablet Veterinary Medicinal Product Carprodyl Quadri 120mg chewable tablets for dogs
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use meloxicam tablets safely and effectively. See full prescribing information for meloxicam tablets.
More informationDevelopment and validation of a HPLC analytical assay method for amlodipine besylate tablets: A Potent Ca +2 channel blocker
Development and validation of a HPLC analytical assay method for amlodipine besylate tablets: A Potent Ca +2 channel blocker Richa Sah* and Saahil Arora 1. ISF College of Pharmacy, Moga, Punjab, India
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Distocur 34 mg/ml Oral suspension for cattle. Distocur.vet 34 mg/ml Oral suspension for cattle. (DK, NO, SE) 2.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FORTEKOR PLUS 1.25 mg/2.5 mg tablets for dogs FORTEKOR PLUS 5 mg/10 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationTreating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P.
Treating Rosacea in the Era of Bacterial Resistance This presentation is sponsored by Galderma Laboratories, L.P. Lecture Discuss rosacea as an inflammatory condition Assess the psychosocial impact of
More informationsingle intravenous and oral doses and after 14 repeated oral
Br. J. clin. Pharmac. (1986), 22, 21-25 The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily J. K. FAULKNER
More information